Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effects (good and bad) and the safety of
Dynavax's immunostimulatory phosphorothiolate oligodeoxyribonucleotide (1018 ISS) given in
combination with Rituxan on patients with B-cell follicular non-Hodgkin's lymphoma. This
research is being done because recurrent follicular non-Hodgkin's lymphoma is not curable
with standard chemotherapy or antibody treatments. 1018 ISS is an experimental compound that
consists of short pieces of DNA that stimulate the immune system. It is hoped that 1018 ISS
may improve the ability of Rituxan to kill cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Dynavax Technologies Corporation James P. Wilmot Cancer Center Massachusetts General Hospital University of Rochester